# Ioannis Parodis

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/ioannis-parodis/

## Facts

| Field | Value |
| --- | --- |
| Citations | 6,647 |
| Field | Systemic Lupus Erythematosus Research |
| h-index | 37 |
| i10-index | 107 |
| Last Known Institution | Karolinska University Hospital |
| OpenAlex ID | https://openalex.org/A5086543859 |
| ORCID iD | 0000-0002-4875-5395 |
| Works | 339 |

## Researcher papers

- [EULAR recommendations for the management of systemic lupus erythematosus: 2023 update](https://scholariq.org/papers/eular-recommendations-for-the-management-of-systemic-lupus-erythematosus-2023/)
- [Lupus nephritis](https://scholariq.org/papers/lupus-nephritis/)
- [2019 Update of the Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA–EDTA) recommendations for the management of lupus nephritis](https://scholariq.org/papers/2019-update-of-the-joint-european-league-against-rheumatism-and-european-renal/)
- [B cell alterations during BAFF inhibition with belimumab in SLE](https://scholariq.org/papers/b-cell-alterations-during-baff-inhibition-with-belimumab-in-sle/)
- [Prediction of prognosis and renal outcome in lupus nephritis](https://scholariq.org/papers/prediction-of-prognosis-and-renal-outcome-in-lupus-nephritis/)
- [EULAR recommendations for the non-pharmacological management of systemic lupus erythematosus and systemic sclerosis](https://scholariq.org/papers/eular-recommendations-for-the-non-pharmacological-management-of-systemic-lupus/)
- [Cardiovascular Disease in Systemic Lupus Erythematosus: Recent Data on Epidemiology, Risk Factors and Prevention](https://scholariq.org/papers/cardiovascular-disease-in-systemic-lupus-erythematosus-recent-data-on/)
- [Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus](https://scholariq.org/papers/smoking-and-pre-existing-organ-damage-reduce-the-efficacy-of-belimumab-in/)
- [The CD6/ALCAM pathway promotes lupus nephritis via T cell–mediated responses](https://scholariq.org/papers/the-cd6-alcam-pathway-promotes-lupus-nephritis-via-t-cell-mediated-responses/)
- [Per-protocol repeat kidney biopsy portends relapse and long-term outcome in incident cases of proliferative lupus nephritis](https://scholariq.org/papers/per-protocol-repeat-kidney-biopsy-portends-relapse-and-long-term-outcome-in/)
- [When should targeted therapies be used in the treatment of lupus nephritis: Early in the disease course or in refractory patients?](https://scholariq.org/papers/when-should-targeted-therapies-be-used-in-the-treatment-of-lupus-nephritis-early/)

## Researcher topics

- [Systemic Lupus Erythematosus Research](https://scholariq.org/topics/systemic-lupus-erythematosus-research/)
- [Rheumatoid Arthritis Research and Therapies](https://scholariq.org/topics/rheumatoid-arthritis-research-and-therapies/)
- [Monoclonal and Polyclonal Antibodies Research](https://scholariq.org/topics/monoclonal-and-polyclonal-antibodies-research/)
- [Systemic Sclerosis and Related Diseases](https://scholariq.org/topics/systemic-sclerosis-and-related-diseases/)
- [Renal Diseases and Glomerulopathies](https://scholariq.org/topics/renal-diseases-and-glomerulopathies/)

## Researcher university

- [Karolinska University Hospital](https://scholariq.org/institutions/karolinska-university-hospital/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.